XFXiaoming Feng

Xiaoming Feng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaoming Feng has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Premarket Regulation of Tissue Engineered Medical Products in China

    by Chunren Wang, Anqi Wang, Xiaoming Feng, Linnan Ke, Yuanli Huang, Qianqian Han, Xue Sun, Zhaopeng Yang

    Tissue engineered medical products (TEMPs) employ state-of-the-art technologies and offer the patients with alternative clinical options for diseases that conventional treatments may fail or be incompetent. However promising, this technology is comparatively new with very limited hands-on experiences with both manufacturing and clinical therapy. Of great significance to products with such complexity and novelty is the establishment of a complete jurisdiction framework and a standardization database so that the safety of the technique in clinical treatment can be ensured. Although different regulatory routes are adopted in different countries, risks are generally considered to be derived from the cellular components within the product, the material scaffolds and potentially from the final products. This article is to provide an insight of the regulatory considerations and the role of China Food and Drug Administration (CFDA) in the supervision of TEMPs.


    • 1 October 2013
      • Vol. 30  (5) , 1058-62

    [The preparation and bioactivity assessment of gene recombinant fibrin-binding brain derived neurotrophic factor].

    by Qianqian Han, Xiaoming Feng, Chunren Wang, Jianwu Dai, Zhaopeng Yang

    Using the E. coli, we fabricated the gene reconstructed brain derived neurotrophic factor with a fibrin binding domain (FBD-BDNF). We then tested the neurotrophic bioactivity and fibrin-binding ability of the FBD-BDNF. The E. coli was used to express the recombinant protein. The inclusion body was purified with column chromatography and renaturated to construct the right 3D formation. In this study, we successfully fabricated the FBD-BDNF and tested the binding ability and neurotrophic activity. The results demonstrated that FBD-BDNF had special binding ability of fibrin and significant neurotrophic activity for DRG cells. FBD-BDNF could have a promising application prospect in nerve tissue engineering.